Members of the MYC family are important oncogenes involved in the development of malignant cells. 1 This may also be the case in multiple myeloma (MM), a malignancy of antibodyproducing plasma cells in bone marrow. The activity of c-MYC in MM increases with disease stage. 2, 3 The mechanism by which c-MYC is activated in each case is unclear; however, multiple signaling pathways converge on c-MYC. Translocations involving MYC and immunoglobulin genes (IG) are relatively rare in MM and considered late progression events. 4 c-MYC regulates transcription of up to 15% of the genes in human cells by binding to its obligate partner MAX. Many cancer cells may develop a dependency on c-MYC activity; and by preventing this activity, the cells may stop dividing or even undergo apoptosis. In agreement with this, short-hairpin RNA targeting MYC was shown to be lethal to a number of human myeloma cell lines. 5 A small-molecule inhibitor, termed 10058-F4, has been identified that is proposed to specifically inhibit c-MYC-MAX heterodimerization, thereby preventing transactivation of c-MYC target genes. 6, 7 The inhibitor has been shown to have growth inhibitory effects on lymphoma and acute myelogenous leukemia cells. 8,9
Introduction
Members of the MYC family are important oncogenes involved in the development of malignant cells. 1 This may also be the case in multiple myeloma (MM), a malignancy of antibodyproducing plasma cells in bone marrow. The activity of c-MYC in MM increases with disease stage. 2, 3 The mechanism by which c-MYC is activated in each case is unclear; however, multiple signaling pathways converge on c-MYC. Translocations involving MYC and immunoglobulin genes (IG) are relatively rare in MM and considered late progression events. 4 c-MYC regulates transcription of up to 15% of the genes in human cells by binding to its obligate partner MAX. Many cancer cells may develop a dependency on c-MYC activity; and by preventing this activity, the cells may stop dividing or even undergo apoptosis. In agreement with this, short-hairpin RNA targeting MYC was shown to be lethal to a number of human myeloma cell lines. 5 A small-molecule inhibitor, termed 10058-F4, has been identified that is proposed to specifically inhibit c-MYC-MAX heterodimerization, thereby preventing transactivation of c-MYC target genes. 6, 7 The inhibitor has been shown to have growth inhibitory effects on lymphoma and acute myelogenous leukemia cells. 8, 9 
Methods

Cells
Myeloma cell lines used in this study were U266, INA-6, JJN-3, KMS-12-BM, IH-1, and KJON. Details on cell culture conditions are found in supplemental Methods (available on the Blood Web site; see the Supplemental Materials link at the top of the online article). CD138 ϩ patient cells obtained through the Norwegian Myeloma Biobank were purified using RoboSep automated cell separator and Human CD138 Positive Selection Kit (Stem Cell Technologies). Bone marrow stromal cells (BMSCs) from patients were obtained by plastic adherence and cultivated as stated in supplemental Methods. The project was approved by the Regional Ethics Committee, and patients gave informed consent in accordance with the Declaration of Helsinki. Patient characteristics are described in supplemental Table 1 .
Cell viability measurements and quantitative RT-PCR were performed as described previously. 10 PCR TaqMan assays used were as follows: MYC, Hs00153408_m1; MYCL1, Hs00420495_m1; and GAPDH, Hs99999905_m1 (Applied Biosystems).
Description of other reagents, immunoblotting, and knockdown experiments is found in supplemental Methods.
Results and discussion
To address the c-MYC dependency of myeloma cells, we decided to evaluate the effect of 10058-F4 in myeloma cell lines and primary cells by in vitro studies. First, both mRNA and protein expression of c-MYC and L-MYC was determined in 6 cell lines by quantitative RT-PCR and immunoblotting ( Figure 1A) . Five of the cell lines expressed c-MYC, whereas U266 only had L-MYC, as previously reported. 11 L-MYC mRNA was also detected in KMS-12-BM and to a lesser extent in INA-6 and JJN-3, although the levels of L-MYC were negligible compared with c-MYC. The effect on cell viability was evaluated in myeloma cell lines treated with increasing concentrations of 10058-F4 for 48 hours. Apoptosis was induced by 50-100M 10058-F4 in all cell lines expressing c-MYC, whereas the U266 cell line, which does not express c-MYC, was only minimally sensitive at 100M ( Figure 1B ). This finding is consistent with the proposal that 10058-F4 is a specific inhibitor of c-MYC-MAX heterodimerization at concentrations Ͻ 100M. There is an Inside Blood commentary on this article in this issue.
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The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked ''advertisement'' in accordance with 18 USC section 1734. For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From 10058-F4 (supplemental Figure 2) . Thus, even though c-MYC and L-MYC share some properties, it is not obvious that L-MYC simply can replace c-MYC in survival of myeloma cells. Interestingly, the 2 cell lines in the panel harboring IG-MYC translocations, 4 JJN-3 and KMS-12-BM, expressed the highest amounts of c-MYC and were less sensitive to the inhibitor than the remaining 3 cell lines. We further measured mRNA expression of MYC and MYCL1 by quantitative RT-PCR in primary myeloma cells purified from bone marrow aspirates (n ϭ 10) or peripheral blood (n ϭ 1; for patient characteristics, see supplemental Table 1 ). All patient cells tested expressed MYC mRNA at similar or higher levels than the cell lines ( Figure 1C) . Next, the effect of the inhibitor on cell viability was evaluated ( Figure 1D ). The cells were incubated with 10058-F4 for 72 hours before staining and analysis as described in Figure 1B . All cells tested were sensitive to the inhibitor, but to various degrees. MM4, MM5, MM7, MM8, and MM10 all had IC 50 Ͻ 50M, whereas the rest of the cell samples had IC 50 Ͼ 50 and Ͻ 100M. The least sensitive cells were from patient MM1. These cells also expressed the highest amount of MYC mRNA of the samples tested, suggesting that more inhibitor may be needed when the cells express relatively high amounts of MYC. For clarity, a comparison between the relative MYC RQ values and the IC 50 of 10058-F4 is provided in supplemental Table 2 .
The 10058-F4 is not applicable in vivo, 13 but it is possible to test effects of the inhibitor in cocultures of myeloma cells and BMSCs. INA-6 cells were added to a monolayer of BMSCs derived from a multiple myeloma patient and treated with 10058-F4 for 3 days before analysis of cell viability. The BMSCs were labeled with the cytosolic dye CFDA-SE before INA-6 cells were added to the culture, making it possible to discriminate between the 2 cell types. INA-6 cells were equally sensitive to apoptosis induced by 10058-F4 in the presence and absence of MM-derived BMSCs (Figure 2A ). In contrast, BMSCs protected INA-6 cells from apoptosis induced by IL-6 deprivation, as previously shown. 14 To further correlate inhibition of c-MYC to apoptosis in myeloma cells, we tested other compounds reported to inhibit or down-regulate c-MYC. The antimalaria drugs artesunate (ART) and dihydroartemisinin (DHA) have been reported to downregulate c-MYC. 15 In addition, in MM cells, treatment with ART or DHA led to induction of apoptosis concomitant with downregulation of c-MYC protein ( Figure 2B-C) . In contrast, lethal doses of PS-341 (bortezomib) did not decrease c-MYC expression ( Figure 2B-C) .
To elucidate the mechanisms involved in apoptosis by the c-MYC inhibitor in MM cells, protein levels of the antiapoptotic Bcl-2 family members Bcl-xL, Mcl-1, and Bcl-2 were measured in INA-6 and U266 after treatment with 10058-F4 for 20 hours ( Figure 2D ). Bcl-xL expression was down-regulated by 10058-F4 in INA-6, but not in the U266 cell line. The effect on Mcl-1 protein expression was minor. Bcl-2 was not detected in INA-6 by immunoblotting, which is in accordance with previous findings. 16 In U266, protein levels of Bcl-2 were clearly BLOOD, 20 SEPTEMBER 2012 ⅐ VOLUME 120, NUMBER 12 For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From detectable but did not change on treatment with the c-MYC inhibitor.
Finally, we treated INA-6, IH-1, and JJN-3 cells with lentiviral short hairpin RNA particles targeting MYC and measured MYC mRNA levels after 2 days and cell viability after 3 days (Figure 2E-F) . Knockdown of MYC lead to decreased viability in all 3 cell lines, in line with previous findings in cell lines 5 and with published data on inhibition of c-MYC using a BET family protein inhibitor, JQ1, that led to a significant reduction of viability in primary cells. 17 Our findings further support the idea that inhibition of c-MYC activity by targeting MYC-MAX heterodimerization may be lethal Mcl-1, Bcl-2, and GAPDH were measured using specific antibodies. (E) Myeloma cell lines were treated with the indicated lentiviral short hairpin RNA particles, and cell viability was evaluated after 3 days. (F) Relative MYC mRNA levels in myeloma cell lines treated for 2 days with the indicated lentiviral short hairpin RNA particles. The relative quantification (RQ) of mRNA levels was calculated using the ␦ ␦ Ct method with GAPDH as housekeeping gene. The MYC mRNA values were set to 1 in the LKO.1-transduced control cells.
